Clinical Trial Update: Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy, safety, and tolerability of AZD9977 in combination with dapagliflozin in participants with heart failure and chronic ki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure

Drugs mentioned

• AZD9977 (AZD9977)
• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure, Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-11-19